['familial partial lipodystrophy', 'hypertriglyceridemia', 'fatty liver', 'nash - nonalcoholic steatohepatitis']
['300mg gemcabene', '600mg gemcabene']

        -  Clinical diagnosis of lipodystrophy based on a lack of body fat in a partial fashion
             assessed by physical examination, and at least 1 MAJOR criterion (below):

          -  Low skinfold thickness in anterior thigh by caliper measurement: men (≤ 10 mm) and
             women (≤ 22 mm) OR

          -  Historic genetic diagnosis of familial partial lipodystrophy (e.g. mutations in LMNA,
             PPAR-γ, AKT2, or PLIN1 genes) as supported by source documentation

          -  Hepatic steatosis (>10% - Stage 2 or 3) as demonstrated by MRI-PDFF;

          -  Alcohol intake of less than 20 g per day in females and 30 g per day in males (one 12
             oz beer, one glass of wine, or 2 oz of spirits or liquor equals roughly 10 g of
             alcohol;

          -  Mean fasting triglyceride value ≥ 250 mg/dL at the Screening Visit;

          -  Background lipid lowering medications must be stable for at least 6 weeks prior to the
             Screening Visit;

          -  Women patients must not be pregnant or lactating and women of child-bearing potential
             must agree to use acceptable methods of contraception throughout the duration of the
             study and for 30 days after the last dose of study drug. Male patients must agree to
             use contraception by means of a condom and may not donate sperm throughout the
             duration of the study and for 8 days after the last dose of study drug.

          -  Weight greater than 50 kg (~110 lbs); with a body mass index (BMI) of no more than 45
             kg/m²;

          -  Have not used a fibrate with in the last 6 weeks and/or thiazolidinediones (TZDs)
             within the last 12 weeks prior to the Screening visit.

          -  Do not have a hypersensitivity or a history of significant reactions of fibrates.

          -  Are not currently taking potent CYP3A4 inhibitors such as itraconazole or a macrolide
             antibiotic.

          -  Have a condition or finding which, in the opinion of the Investigator, would
             compromise the patient's safety or participation in the study.
      